OR WAIT null SECS
November 18, 2026
Video
UNOS data on 82,014 candidates show ALD accounted for 39.0% of steatotic liver disease transplant listings from 2014 to 2024.
November 16, 2026
Patricia Bloom, MD, examines microbiome therapies for hepatic encephalopathy, FMT findings, and challenges in HE drug development.
Patricia Bloom, MD, discusses treatment gaps in hepatic encephalopathy and the role of adjunctive therapies in 2026 ACG guidance.
November 13, 2026
Nancy Reau, MD, discusses ECLIPSE 1 data showing monthly elebsiran plus tobevibart achieved undetectable HDV RNA in 79% of patients with hepatitis delta.
November 12, 2026
AZURE-1 enrolled participants with cirrhosis, portal hypertension, and HIV, offering insight into how brelovitug may fit real-world hepatitis D care.
November 11, 2026
Late-breaking data presented at AASLD 2026 showed brelovitug met the phase 3 primary endpoint in chronic hepatitis D, with no treatment-related serious adverse events.
New survey data from 42 countries show high antiviral adherence among people with HBV, but 64% of those untreated receive no hepatitis B care.
Pharmacovigilance data on 328 pregnancies exposed to glecaprevir/pibrentasvir presented at AASLD 2026 showed no vertical transmission and no pattern of congenital anomalies.
Podcast
Jasmohan Bajaj, MD, MS, joins Nancy Reau, MD, and Kimberly Brown, MD, on who to screen for HE in clinic and how to prepare patients and families.